Abstract
Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.
Original language | English |
---|---|
Pages (from-to) | 2011-2014 |
Number of pages | 4 |
Journal | Clinical Case Reports |
Volume | 6 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 2018 |
Keywords
- bleomycin
- infliximab
- intensive care
- pulmonary toxicity
- respiratory failure
- treatment outcome